Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Brian Adams Biography and Net Worth

General Counsel of Relay Therapeutics

Brian Adams brings to Relay more than 15 years of legal and business management experience within the life sciences. Brian joined the company from Keryx Biopharmaceuticals, where he served as senior vice president, general counsel and secretary. Prior to Keryx, he held roles in Algeta ASA, AVEO Oncology and Genzyme Corporation. Before joining Genzyme, Brian practiced at Bingham McCutchen LLP, where he advised private equity sponsors, biotech and other emerging technology companies on a broad range of corporate matters and financing transactions.

Brian holds a B.A. from Harvard University and a J.D. from the Catholic University of America’s Columbus School of Law.

What is Brian Adams' net worth?: The estimated net worth of Brian Adams is at least $263,065.76 as of January 12th, 2023. Mr. Adams owns 51,531 shares of Relay Therapeutics stock worth more than $263,066 as of November 17th. This net worth approximation does not reflect any other investments that Mr. Adams may own. Additionally, Mr. Adams receives an annual salary of $627,720.00 as General Counsel at Relay Therapeutics. Learn More about Brian Adams' net worth.
How old is Brian Adams?: Mr. Adams is currently 50 years old. There are 5 older executives and no younger executives at Relay Therapeutics. The oldest executive at Relay Therapeutics is Dr. David Elliot Shaw Ph.D., Founder, who is 73 years old. Learn More on Brian Adams' age.
What is Brian Adams' salary?: As the General Counsel of Relay Therapeutics, Inc., Mr. Adams earns $627,720.00 per year. There are 3 executives that earn more than Mr. Adams. The highest earning executive at Relay Therapeutics is Dr. Donald A. Bergstrom M.D., Ph.D., President of Research & Development, who commands a salary of $1,370,000.00 per year. Learn More on Brian Adams' salary.
How do I contact Brian Adams?: The corporate mailing address for Mr. Adams and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at [email protected]. Learn More on Brian Adams' contact information.
Has Brian Adams been buying or selling shares of Relay Therapeutics?: Brian Adams has not been actively trading shares of Relay Therapeutics within the last three months. Most recently, Brian Adams sold 9,994 shares of the business's stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $20.00, for a transaction totalling $199,880.00. Following the completion of the sale, the insider now directly owns 51,531 shares of the company's stock, valued at $1,030,620. Learn More on Brian Adams' trading history.
Who are Relay Therapeutics' active insiders?: Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), and Andy Porter (Insider). Learn More on Relay Therapeutics' active insiders.
Are insiders buying or selling shares of Relay Therapeutics?: In the last twelve months, insiders at the sold shares 18 times. They sold a total of 141,822 shares worth more than $1,108,841.14. The most recent insider tranaction occured on October, 28th when insider Peter Rahmer sold 1,621 shares worth more than $9,823.26. Insiders at Relay Therapeutics own 4.3% of the company. Learn More about insider trades at Relay Therapeutics.
Information on this page was last updated on 10/28/2024.

Brian Adams Insider Trading History at Relay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2023	Sell	9,994	$20.00	$199,880.00	51,531
9/27/2022	Sell	294	$22.73	$6,682.62	62,548
11/15/2021	Sell	6,500	$35.42	$230,230.00
9/13/2021	Sell	6,500	$35.02	$227,630.00	32,077
6/7/2021	Sell	6,500	$35.00	$227,500.00	32,370
4/26/2021	Sell	6,500	$35.00	$227,500.00	32,370
1/28/2021	Sell	5,000	$55.05	$275,250.00	15,000

Brian Adams Buying and Selling Activity at Relay Therapeutics

Relay Therapeutics Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $5.11

$5.03

$5.63

50 Day Range

MA: $6.71

$5.11

$9.51

2 Week Range

Now: $5.11

$5.03

$12.14

Volume

1,925,087 shs

Average Volume

1,251,957 shs

Market Capitalization

$854.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Has Trump Finally Gone Too Far?

From Insiders Exposed | Ad

Brian Adams Biography and Net Worth

What is Brian Adams' net worth?

How old is Brian Adams?

What is Brian Adams' salary?

How do I contact Brian Adams?

Has Brian Adams been buying or selling shares of Relay Therapeutics?

Who are Relay Therapeutics' active insiders?

Are insiders buying or selling shares of Relay Therapeutics?